ATE218869T1 - Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen - Google Patents

Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Info

Publication number
ATE218869T1
ATE218869T1 AT94926719T AT94926719T ATE218869T1 AT E218869 T1 ATE218869 T1 AT E218869T1 AT 94926719 T AT94926719 T AT 94926719T AT 94926719 T AT94926719 T AT 94926719T AT E218869 T1 ATE218869 T1 AT E218869T1
Authority
AT
Austria
Prior art keywords
treatment
vasodilating
ingredients
liver diseases
similar indications
Prior art date
Application number
AT94926719T
Other languages
English (en)
Inventor
Allan Joseph Mcclean
Original Assignee
Pharmacy And Therapeutic Advis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacy And Therapeutic Advis filed Critical Pharmacy And Therapeutic Advis
Application granted granted Critical
Publication of ATE218869T1 publication Critical patent/ATE218869T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
AT94926719T 1993-09-08 1994-09-05 Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen ATE218869T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM110493 1993-09-08
PCT/AU1994/000525 WO1995007080A1 (en) 1993-09-08 1994-09-05 A method of treating liver disease and like indications with vasodilating agents

Publications (1)

Publication Number Publication Date
ATE218869T1 true ATE218869T1 (de) 2002-06-15

Family

ID=3777184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94926719T ATE218869T1 (de) 1993-09-08 1994-09-05 Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Country Status (13)

Country Link
EP (1) EP0717625B1 (de)
JP (1) JP3842815B2 (de)
KR (1) KR100350156B1 (de)
CN (1) CN1115151C (de)
AT (1) ATE218869T1 (de)
CA (1) CA2170289C (de)
DE (1) DE69430807T2 (de)
FI (1) FI961029L (de)
IL (1) IL110888A (de)
NO (1) NO960866D0 (de)
NZ (1) NZ273242A (de)
SG (1) SG49645A1 (de)
WO (1) WO1995007080A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174917B1 (en) 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502143B1 (de) * 1990-09-07 1995-11-08 Universidad De Alicante Komposition für die behandlung von augenschmerzen
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation

Also Published As

Publication number Publication date
CA2170289C (en) 2001-05-08
DE69430807D1 (de) 2002-07-18
CA2170289A1 (en) 1995-03-16
CN1130874A (zh) 1996-09-11
NO960866L (no) 1996-03-04
JP3842815B2 (ja) 2006-11-08
WO1995007080A1 (en) 1995-03-16
KR100350156B1 (ko) 2003-02-14
DE69430807T2 (de) 2002-12-19
FI961029A0 (fi) 1996-03-06
CN1115151C (zh) 2003-07-23
EP0717625A1 (de) 1996-06-26
EP0717625B1 (de) 2002-06-12
SG49645A1 (en) 1999-10-19
IL110888A (en) 1999-07-14
HK1003422A1 (en) 1998-10-30
FI961029A7 (fi) 1996-03-06
JPH09502188A (ja) 1997-03-04
IL110888A0 (en) 1994-11-28
NZ273242A (en) 2001-04-27
NO960866D0 (no) 1996-03-04
FI961029L (fi) 1996-03-06
EP0717625A4 (de) 1997-12-29

Similar Documents

Publication Publication Date Title
ATE221377T1 (de) Verfahren zur reduzierung der körperfettanteils bei tieren mit der verabreichungvon konjugiergter linolsäure
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
ATE62414T1 (de) Mittel zur behandlung von herzerkrankungen.
DE69512685D1 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
EE9900428A (et) Köhavastased ravimkoostised
ATE133859T1 (de) Pharmazeutische zubereitungen mit verzögerter freisetzung zur behandlung periodontaler erkrankungen
ATE222109T1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69813354D1 (de) Mittel zur Behandlung von Herzkrankheiten
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
DE68905479D1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
ATE81587T1 (de) Medizinisches praeparat zur behandlung von hautleiden.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee